A Phase 3, Randomized, Study to Assess the Efficacy and Safety of Ublituximab in Combination with Ibrutinib Compared to Ibrutinib Alone, in Patients with Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL).

UCI-14-87
NCT02301156
Cancer - Lymphoid Leukemia, Cancer - Non-Hodgkin's Lymphoma
Edward L Nelson
Open
Treatment
Ibrutinib, Ublituximab
III
Adult
Local

For information about cancer clinical trials at the UC Irvine Health Chao Family Comprehensive Cancer Center, call toll-free 877-UC-STUDY (877-827-8839) or email ucstudy@uci.edu.